{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"3.0","value":"2.7"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"3.2","value":"2.7"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"3.6","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG000","title":"Dose Level 1: 170mcg LMB-100"},{"description":"Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG001","title":"Dose Level -1: 140mcg LMB-100"},{"description":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.","id":"OG002","title":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At progression, up to 3.6 months","title":"Median Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}